-
Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn
pharmaceutical-technology
March 29, 2017
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn.
-
Smoking Slows Recovery From Drug Abuse
drugs
March 28, 2017
People recovering from illicit drug abuse are more likely to be successful if they don't smoke cigarettes
-
Pfizer bags approval for RA drug Xeljanz
pharmatimes
March 28, 2017
Some patients with moderate to severe forms of rheumatoid arthritis could get access to a new treatment option in Europe following the approval of Pfizer’s oral Janus kinase (JAK) ...
-
Shire’s rare blood disorder drug gets US fast track
pharmatimes
March 24, 2017
An experimental therapy in development by Shire for patients with the rare blood disorder hereditary thrombotic thrombocytopenic purpura (hTTP) has been granted a fast track designation by the US Food and Drug Administration.
-
NICE backs use of drugs for breast cancer prevention
pharmatimes
March 24, 2017
The National Institute for Health and Care Excellence has now published updated familial breast cancer guidelines which advocate the use of three medicines to reduce the risk of developing the disease.
-
British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C
firstwordpharma
March 23, 2017
Gilead Sciences Canada, Inc. ( Gilead Canada ) today announced, effective March 21, 2017 , British Columbia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets.
-
Drug No Better Than Placebo for Lower Back, Leg Pain
drugs.com
March 23, 2017
The widely prescribed pain drug pregabalin (brand name: Lyrica) may be no better than a placebo when it comes to treating the back and leg pain known as sciatica, a new clinical trial suggests.
-
Bellus Health agrees to sell Thallion to US firm Taro Pharmaceuticals
pharmaceutical-technology
March 21, 2017
Bellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the...
-
Cost of prescriptions to rise 20p in England
pharmatimes
March 20, 2017
The prescription charge in England will rise next month by 20 pence to £8.60 for each medicine or appliance ...
-
BELLUS Health Sells Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
americanpharmaceuticalreview
March 20, 2017
BELLUS Health Inc. has entered into a share purchase agreement with Taro Pharmaceuticals Inc. for the sale of BELLUS Health's wholly-owned subsidiary Thallion Pharmaceuticals Inc. including all the rights to the drug candidate ShigamabTM.